SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES
July 18, 2019 06:45 ET
|
Silence Therapeutics
SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES -- Collaboration advances Silence’s proprietary platform...
SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia
January 15, 2019 07:00 ET
|
Silence Therapeutics
SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia January 15, 2019 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery,...
Silence Therapeutics advances next RNAi medicine
December 19, 2018 07:00 ET
|
Silence Therapeutics
Silence Therapeutics advances next RNAi medicine Lipoprotein(a) targeting, an exciting approach to address cardiovascular disease December 19, 2018 LONDON, Silence Therapeutics, PLC (LON: SLN)...